share_log

Vivos Therapeutics | 424B1: Prospectus

Vivos Therapeutics | 424B1: Prospectus

Vivos Therapeutics | 424B1：募资说明书
美股sec公告 ·  04/26 17:10
Moomoo AI 已提取核心信息
Vivos Therapeutics, Inc., a medical technology company, has filed a prospectus related to the sale of 1,737,259 shares of common stock. The shares are being offered by a selling stockholder, Armistice Capital, LLC, and are associated with common stock purchase warrants issued in private placements that occurred in January and November of 2023, and February of 2024. The company will not receive any proceeds from the sale of the common stock by the selling stockholder. However, proceeds may be received upon the exercise of the warrants for cash, which will be used for general corporate purposes and working capital. The common stock is listed on the Nasdaq under the symbol 'VVOS.' As of April 4, 2024, the last reported sale price of Vivos Therapeutics' common stock was $3.01 per share. The company is identified as an 'emerging growth company' and is subject to reduced public company reporting requirements. The prospectus also includes a cautionary note regarding forward-looking statements and details the risks involved in investing in the common stock.
Vivos Therapeutics, Inc., a medical technology company, has filed a prospectus related to the sale of 1,737,259 shares of common stock. The shares are being offered by a selling stockholder, Armistice Capital, LLC, and are associated with common stock purchase warrants issued in private placements that occurred in January and November of 2023, and February of 2024. The company will not receive any proceeds from the sale of the common stock by the selling stockholder. However, proceeds may be received upon the exercise of the warrants for cash, which will be used for general corporate purposes and working capital. The common stock is listed on the Nasdaq under the symbol 'VVOS.' As of April 4, 2024, the last reported sale price of Vivos Therapeutics' common stock was $3.01 per share. The company is identified as an 'emerging growth company' and is subject to reduced public company reporting requirements. The prospectus also includes a cautionary note regarding forward-looking statements and details the risks involved in investing in the common stock.
医疗技术公司Vivos Therapeutics, Inc. 已提交了一份与出售1,737,259股普通股有关的招股说明书。这些股票由出售股东Armistice Capital, LLC发行，与2023年1月和11月以及2024年2月以私募方式发行的普通股购买权证有关。该公司不会从出售普通股的股东出售普通股中获得任何收益。但是，在行使认股权证时可能会收到收益，现金将用于一般公司用途和营运资金。普通股在纳斯达克上市，股票代码为 “VVOS”。截至2024年4月4日，Vivos Therapeutics普通股最新公布的销售价格为每股3.01美元。该公司被认定为 “新兴成长型公司”，上市公司报告要求有所降低。招股说明书还包括有关前瞻性陈述的警示说明，并详细说明了投资普通股所涉及的风险。
医疗技术公司Vivos Therapeutics, Inc. 已提交了一份与出售1,737,259股普通股有关的招股说明书。这些股票由出售股东Armistice Capital, LLC发行，与2023年1月和11月以及2024年2月以私募方式发行的普通股购买权证有关。该公司不会从出售普通股的股东出售普通股中获得任何收益。但是，在行使认股权证时可能会收到收益，现金将用于一般公司用途和营运资金。普通股在纳斯达克上市，股票代码为 “VVOS”。截至2024年4月4日，Vivos Therapeutics普通股最新公布的销售价格为每股3.01美元。该公司被认定为 “新兴成长型公司”，上市公司报告要求有所降低。招股说明书还包括有关前瞻性陈述的警示说明，并详细说明了投资普通股所涉及的风险。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息